Medical Countermeasures Advanced Research, Development and Acquisition Contract and Grant Awards
- September 29, 2014: New device could reduce time needed to test for bacteria, such as anthrax
- September 15, 2014: New diagnostic test to detect the presence of an influenza virus and identify its genetic profile
- October 21, 2013: New blood test would provide fast results for medical care after anthrax attack
- September 26, 2013: BARDA boosts global ability to respond to pandemics
- September 20, 2013: HHS funds development of freeze-dried platelets for disaster response
- September 19, 2013: BARDA funds development of device to aid burn patients in disasters
- September 19, 2013: HHS replenishes nation’s supply of anthrax antitoxin
- September 18, 2013: HHS explores new emergency response use for approved steroid
- September 17, 2013: BARDA funds study of therapy for thermal burns
- September 16, 2013: BARDA evaluates burn dressing for radiation, sulfur mustard burns
- August 23, 2013: BARDA Contract Supports Evaluation of Therapy for Severe Thermal Burns
- August 22, 2013: BARDA Supports Proof-Of-Concept Studies for Small Molecule Development
- July 30, 2013: BARDA contract supports the development of a more effective skin graft to help burn patients after a rad/nuke event
- June 25, 2013: BARDA supports new broad-spectrum antibiotic against glanders, melioidosis
- May 24, 2013: BARDA supports new broad-spectrum antibiotic to treat anthrax, tulermia
- May 22, 2013: HHS forms strategic alliance to develop new antibiotics
- April 3, 2013: HHS awards contract to create test to identify resistant influenza viruses
- December 13, 2012: BARDA, Johns Hopkins Partner to Explore Impact of Rapid, Near-Patient Flu Tests
- January 20, 2012: HHS aids development of next generation broad spectrum antibiotic
- September 29, 2011: BARDA funds development of oral drug to treat internal contamination from radioactive elements
- September 28, 2011: Cushing’s disease drug studied for possible use in treating gastrointestinal injuries from radiation exposure
- September 28, 2011: Studies to continue in development of new way to treat blood damage from radiation
- September 28, 2011: Contract awarded to develop drug to protect against radiation-induced gastrointestinal injury
- September 16, 2011: Licensed anthrax vaccine undergoes temperature studies
- September 15, 2011: BARDA funds advanced development of drug to treat bone marrow injury associated with acute radiation syndrome
- September 15, 2011: Novel anthrax vaccine being developed with BARDA support
- September 6, 2011: BARDA partners with GlaxoSmithKline to develop new class of antibiotic against bioterrorism threats and Gram-negative infections
- August 31, 2011: Anti-inflammatory drug studied for use 24 hours or longer after exposure to radiation
- August 30, 2011: BARDA funds development of drugs to treat injuries from chemical bioterrorism
- August 30, 2011: BARDA supports development of antitoxin administered as a traditional shot
- August 30, 2011: BARDA funds advanced development of drug to treat injuries from exposure to cyanide
0 Likes
